The Company

Cellics Therapeutics, Inc. is a biotechnology company founded by Dr. Liangfang Zhang, the Joan and Irwin Jacobs Chancellor Professor at UC San Diego, and the Scientific Founder of Cellics, based on his award-winning Cellular Nanoparticle (CNP) Technology. The company is pioneering drug delivery and therapeutics using its two nanoplatforms, Cellular Nanosponges, and the Cellular Nanoparticle drug delivery platform. Cellics goal is to broadly apply its proprietary CNP technology to better treat and prevent serious diseases with high unmet medical needs. 

The CNP drug delivery platform focuses on developing Cellular Nanoparticles for the delivery of mRNA, siRNA, proteins, and small molecules for improved intracellular delivery efficiency and increased cell targeting.  

The CNP Nanosponge platform focuses on developing therapeutics for inflammatory, autoimmune, and difficult-to-treat infectious diseases. In May of 2022, Cellics received IND allowance for its Red Blood Cell Nanosponge, for patients hospitalized with methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-sensitive Staphylococcus aureus (MSSA) pneumonia.